Skip to content

Merus NV Sustainability Reports

Merus N.V. is a clinical-stage oncology biotechnology company that discovers and develops innovative multispecific antibody therapeutics. Its proprietary Multiclonics platforms are designed to generate therapies that engage multiple targets to enhance anti-cancer effects.

Sector: Manufacturing

Country: Netherlands

Exchange: Nasdaq

LEI: 549300W8GPUWU8QNU293

FIGI: BBG00B8LXMT4

No reports are currently available in our catalogue.